Well RCE weren't the only ones chosen-:
https://getthewordout.com.au/press-...-promising-covid-19-virus-laboratory-results/Pixatimod is currently in Phase 1b clinical trials for advanced cancer in Australia, and given the company has an open Investigational New Drug (IND) with the USFDA, this is anticipated to expedite clinical testing in the United States.
Pixatimod was also
recently selected as a Priority Group 1 asset for laboratory testing by the CSIRO/Doherty Institute as part of the SARS-CoV-2 Antiviral and Antiseptic Screening Program.The company announced plans on 20 March 2020 to undertake investigations on the well- established antiviral properties of pixatimod in relation to SARS-CoV-2. Over the past three months, Zucero has been working with national and international academic collaborators who have been assessing pixatimod’s antiviral properties, including in a number of in vitro live virus infectivity studies. This includes collaborators from institutions such as the University of Liverpool (UK), Keele University (UK), Public Health England (UK), the University of Gothenburg (Sweden), Queensland University of Technology and The University of Queensland.
Zucero is now pleased to advise the in vitro studies clearly demonstrated that pixatimod binds directly to the SARS-CoV-2 spike protein S1 receptor binding domain (RBD) which alters its conformation
I know of another company that had some pretty good results with the SARS-CoV-2?
Any guesses?
